Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …

Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median
overall survival of only about 13 months, indicating the urgent need for novel therapies …

The persistence of cancer cells resistant to therapy remains a major clinical challenge. In
triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence …

Small cell lung cancer (SCLC) exists broadly in four molecular subtypes: ASCL1,
NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually …

Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …

Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with
hitherto unseen responses at advanced and metastatic stages of the disease. However, the …

KRAS-LKB1 (KL) mutant lung cancers silence STING owing to intrinsic mitochondrial
dysfunction, resulting in T cell exclusion and resistance to programmed cell death (ligand) 1 …

While STING-activating agents have shown limited efficacy in early-phase clinical trials,
multiple lines of evidence suggest the importance of tumor cell-intrinsic STING function in …